
09/26/2025
GLP-1s aren't just for weight loss and glucose control. Studies are constantly showing benefits outside of that scope and why they are doing so much good.
🔬 GLP-1 meds lower pro-inflammatory markers: C-reactive protein (CRP), Interleukin-6 (IL-6) and Tumor necrosis factor-alpha (TNF-α).This reduction can lead to improved insulin sensitivity, better cardiovascular outcomes, and lower overall inflammatory burden in chronic diseases.
❤️ Cardiovascular Inflammation is reduced. Improvement in endothelial function (lining of blood vessels). Decreased oxidative stress, which damages blood vessels. These effects may partly explain the cardiovascular protection seen in trials like LEADER and SUSTAIN-6.
🧠Emerging research suggests GLP-1s cross the blood-brain barrier and may reduce neuroinflammation involved in diseases like Alzheimer’s and Parkinson’s. Possibly modulate microglial activation, which is linked to brain aging and degeneration.
Some trials are currently testing GLP-1 drugs in neurodegenerative diseases.
⚙️ Non-alcoholic fatty liver disease (NAFLD) and its more severe form (NASH) are tied to metabolic inflammation. GLP-1s reduce hepatic fat accumulation, lower ALT/AST liver enzymes and improve liver histology (in clinical trials with semaglutide).